TC BioPharm (NASDAQTCBP), a clinical-stage biotech company, announced plans to initiate Proof of Concept preclinical studies for its lead therapy, TCB008, targeting H5N1 “bird flu.” TCB008 is an allogeneic gamma delta T cell therapy designed to leverage the immune system against infections like H5N1, which recently caused the first reported U.S. fatality in Louisiana. TC BioPharm aims to collaborate with leading infectious disease centers or universities to expedite studies and prepare for a Phase I trial. CEO Bryan Kobel emphasized TCB008’s potential in addressing infectious diseases, underscoring the company’s commitment to combating emerging health threats.

TC BioPharm (NASDAQTCBP), a clinical-stage biotechnology company advancing allogeneic gamma-delta T cell therapies for cancer and other diseases, announced that CEO Bryan Kobel will present a corporate overview at the Sequire Investor Summit 2025. The conference will take place Jan. 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

TC BioPharm (NASDAQTCBP), a clinical-stage biotech company focused on gamma-delta T cell therapies for cancer, announced that its American Depository Shares remain actively traded on the Nasdaq Global Select Market under the ticker symbol “TCBP.” The company clarified that there has been no trading halt and that shares are expected to trade without interruption. This announcement does not constitute any offer or solicitation regarding securities transactions.

TC BioPharm (NASDAQTCBP), a clinical-stage biotechnology company focused on gamma-delta T cell therapies, announced shareholder approval of a 25% special stock dividend. Shareholders of record as of Jan. 2, 2025, will receive 0.25 American Depositary Shares (“ADSs”) for every 1 ADS held, with distribution expected around January 6, 2025. CEO Bryan Kobel emphasized the dividend as a reflection of confidence in the company’s financial outlook and a strategic move to enhance shareholder value. Nasdaq trading of TCBP ADSs will pause temporarily from January 2 to January 8 to facilitate the dividend process.

TC BioPharm (NASDAQTCBP) announced encouraging progress in its ACHIEVE Phase 2b trial in the UK, with three patients completing the full-dose regimen of TCB008 with no drug-related adverse events. The trial, evaluating TCB008 for AML and MDS/AML, has enrolled 10 patients so far, with nine receiving their second dose, four their third dose, and three their final dose. Preliminary safety data indicates the 5mL dose is well-tolerated, supporting the study’s safety objectives. Recruitment has advanced swiftly, with nine of 14 planned patients for Cohort A (relapsed/refractory disease) and one for Cohort B (minimal residual disease) enrolled. Company executives noted the trial’s rapid progress and the potential for expedited review in Cohort B, as the team focuses on completing recruitment and data analysis in 2025.

TC BioPharm (NASDAQTCBP) has announced a special dividend of 0.25 American Depositary Shares (“ADSs”) for every 1 ADS held, subject to shareholder approval. The decision will be discussed during a General Meeting on December 30, 2024, in Scotland, with the dividend payable to shareholders holding stock at market close on January 2, 2025. CEO Bryan Kobel highlighted the dividend as a reward for shareholder loyalty amid challenging market conditions and expressed confidence in delivering further operational successes in 2025. Details are available on the company’s website and the SEC’s platform.

TC BioPharm to issue a special dividend of 0.25 ADS per share, pending shareholder approval at the December 30 meeting. Record date: January 2, 2025.

TC BioPharm (NASDAQTCBP), a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, has partnered with CareDx, Inc. NASDAQ: CDNANASDAQCDNA)

TC BioPharm (NASDAQTCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, has announced an update on the progression of the ACHIEVE UK Trial. “Medicinal products cannot be effective if they are not safe, and it’s clear from these initial data that TCB008 is safe for our patients,” said Executive VP of Clinical Operations, Alison Bracchi. “Our priority now, for Cohort A, is to find the optimal biologically effective dose for patients that have exhausted all other treatments to drive a long term response. We look forward to completing the recruitment of Cohort B patients and are planning to evaluate these data in the first half of 2025.”

Standard Lithium (NYSE American: SLI) reported robust fiscal Q1 2025 progress, highlighted by a $225 million conditional grant from the U.S. Department of Energy, marking one of the largest grants awarded to a U.S. critical minerals project. This funding supports the construction of Phase 1 for the South West Arkansas (“SWA”) lithium project, anticipated to produce 22,500 tonnes of lithium carbonate annually by 2028. David Park, newly appointed CEO, is steering the company’s focus toward production, advancing off-take agreements, and partnering with Equinor. Additionally, Standard Lithium has adopted Koch Technology Solutions’ advanced lithium extraction technology for use in the SWA project’s commercial facility.

TC BioPharm (NASDAQTCBP), a clinical-stage biotech firm developing gamma-delta T cell therapies, reported key 2024 achievements, highlighting progress in the ACHIEVE UK trial, with eight patients dosed and new trial sites established, including Guy’s and St. Thomas Hospital. The company also launched a compassionate use program for TCB008 and signed two non-binding LOIs for potential acquisitions in CAR-T and NK therapy technologies. TC BioPharm collaborated with the University of Surrey on preclinical Mpox studies and partnered with Carnegie Mellon University on AI-driven donor screening for cell therapies. Cost efficiencies have increased treatment capacity, while a Q3 capital raise of $8 million bolstered its balance sheet, positioning TC BioPharm to continue advancing its strategic initiatives into 2025.

TC BioPharm (NASDAQTCBP) a clinical-stage biotech company, has partnered with Dr. Carlos Maluquer de Motes from the University of Surrey to develop a gamma-delta T cell therapy for Monkeypox. The collaboration aims to leverage TC BioPharm’s lead therapeutic, TCB008, to enhance immune response and explore its use in treating and preventing viral infections. The research focuses on bolstering gamma-delta T cells to improve outcomes for patients with severe viral infections, such as Monkeypox, which has caused over 100,000 cases globally since 2022.

TC BioPharm (NASDAQTCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, today announced its sponsored research agreement with Carnegie Mellon University. Under the agreement, TC BioPharm is partnering with Dr. Wei Wu, a faculty member in the Ray and Stephanie Lane Computational Biology Department within the university’s School of Computer Science, and her lab to explore the potential use of artificial intelligence (“AI”) to enhance the donor selection and matching processes.

TC BioPharm (NASDAQTCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, is announcing Guys and St. Thomas Hospital, a London-based hospital with a leading oncology clinic and cell therapy clinical team, as a new site in the ACHIEVE UK Trial. The site opened in September 2024, expediting the progression of the trial timelines and increasing the velocity of enrollment. The ACHIEVE UK clinical trial is an open-label, Phase 2 study evaluating the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease.